PMID- 28993945
OWN - NLM
STAT- MEDLINE
DCOM- 20180109
LR  - 20220410
IS  - 1432-1335 (Electronic)
IS  - 0171-5216 (Linking)
VI  - 144
IP  - 1
DP  - 2018 Jan
TI  - Drug-eluting bead transarterial chemoembolization in the treatment for 
      unresectable soft tissue sarcoma refractory to systemic chemotherapy: a 
      preliminary evaluation of efficacy and safety.
PG  - 157-163
LID - 10.1007/s00432-017-2530-3 [doi]
AB  - PURPOSE: To preliminarily evaluate the clinical efficacy and safety of 
      drug-eluting bead transarterial chemoembolization (DEB-TACE) for unresectable 
      soft tissue sarcoma refractory to systemic chemotherapy. METHODS: Ten patients 
      with refractory sarcoma who underwent DEB-TACE therapy between January 2015 and 
      January 2017 were identified. Clinical information and radiological data were 
      retrospectively collected to analyze tumor response, overall survival (OS), 
      progression-free survival and adverse events (AEs). Tumor response to DEB-TACE 
      was assessed with modified Response Evaluation Criteria in Solid Tumors (mRECIST) 
      guidelines applied to computed tomography or magnetic resonance imaging. RESULTS: 
      All DEB-TACE procedures were successfully performed for ten patients with 15 
      tumor lesions. The median follow-up duration was 19 months and the median 
      survival time was 21 months (range 11-30 months). The 1- and 2-year OS rate was 
      90 and 30%, respectively. According to the guidance of mRECIST, complete 
      response, partial response, stable disease and progressive disease were noted in 
      zero (0%), three (30%), four (40%) and three (30%) patients, respectively. The 
      disease control rate and objective response rate was 70 and 30%, respectively. 
      There were no serious AEs in patients after DEB-TACE. CONCLUSIONS: Our data 
      showed that DEB-TACE was effective and safe for patients with soft tissue 
      sarcoma. Therefore, DEB-TACE can be considered as an alternative treatment option 
      for unresectable soft tissue sarcoma refractory to conventionally systemic 
      chemotherapy.
FAU - Ni, Jia-Yan
AU  - Ni JY
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene 
      Regulation, Department of Interventional Radiology, Sun Yat-Sen Memorial 
      Hospital, Sun Yat-Sen University, No. 107 Yanjiang Road West, Guangzhou, 510120, 
      Guangdong, People's Republic of China.
FAU - Sun, Hong-Liang
AU  - Sun HL
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene 
      Regulation, Department of Interventional Radiology, Sun Yat-Sen Memorial 
      Hospital, Sun Yat-Sen University, No. 107 Yanjiang Road West, Guangzhou, 510120, 
      Guangdong, People's Republic of China.
FAU - Chen, Yao-Ting
AU  - Chen YT
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene 
      Regulation, Department of Interventional Radiology, Sun Yat-Sen Memorial 
      Hospital, Sun Yat-Sen University, No. 107 Yanjiang Road West, Guangzhou, 510120, 
      Guangdong, People's Republic of China.
FAU - Luo, Jiang-Hong
AU  - Luo JH
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene 
      Regulation, Department of Interventional Radiology, Sun Yat-Sen Memorial 
      Hospital, Sun Yat-Sen University, No. 107 Yanjiang Road West, Guangzhou, 510120, 
      Guangdong, People's Republic of China.
FAU - Wang, Wei-Dong
AU  - Wang WD
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene 
      Regulation, Department of Interventional Radiology, Sun Yat-Sen Memorial 
      Hospital, Sun Yat-Sen University, No. 107 Yanjiang Road West, Guangzhou, 510120, 
      Guangdong, People's Republic of China.
FAU - Jiang, Xiong-Ying
AU  - Jiang XY
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene 
      Regulation, Department of Interventional Radiology, Sun Yat-Sen Memorial 
      Hospital, Sun Yat-Sen University, No. 107 Yanjiang Road West, Guangzhou, 510120, 
      Guangdong, People's Republic of China.
FAU - Chen, Dong
AU  - Chen D
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene 
      Regulation, Department of Interventional Radiology, Sun Yat-Sen Memorial 
      Hospital, Sun Yat-Sen University, No. 107 Yanjiang Road West, Guangzhou, 510120, 
      Guangdong, People's Republic of China.
FAU - Xu, Lin-Feng
AU  - Xu LF
AUID- ORCID: 0000-0002-4217-328X
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene 
      Regulation, Department of Interventional Radiology, Sun Yat-Sen Memorial 
      Hospital, Sun Yat-Sen University, No. 107 Yanjiang Road West, Guangzhou, 510120, 
      Guangdong, People's Republic of China. xu_lin_feng@163.com.
LA  - eng
PT  - Journal Article
DEP - 20171009
PL  - Germany
TA  - J Cancer Res Clin Oncol
JT  - Journal of cancer research and clinical oncology
JID - 7902060
SB  - IM
MH  - Adult
MH  - Chemoembolization, Therapeutic/adverse effects/*methods
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Sarcoma/blood supply/*therapy
MH  - Survival Rate
OTO - NOTNLM
OT  - Drug-eluting bead
OT  - Soft tissue sarcoma
OT  - Systemic chemotherapy
OT  - Transarterial chemoembolization
EDAT- 2017/10/11 06:00
MHDA- 2018/01/10 06:00
CRDT- 2017/10/11 06:00
PHST- 2017/09/21 00:00 [received]
PHST- 2017/10/03 00:00 [accepted]
PHST- 2017/10/11 06:00 [pubmed]
PHST- 2018/01/10 06:00 [medline]
PHST- 2017/10/11 06:00 [entrez]
AID - 10.1007/s00432-017-2530-3 [pii]
AID - 10.1007/s00432-017-2530-3 [doi]
PST - ppublish
SO  - J Cancer Res Clin Oncol. 2018 Jan;144(1):157-163. doi: 10.1007/s00432-017-2530-3. 
      Epub 2017 Oct 9.